Page 517 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

17. MITOXANTRONE 475

VUKOVIC V., TANNOCK I.F., Influence ol low pH on cytotoxicity of paclitaxel, mitoxan-
trone and topotecan, Br. J. Cancer, 1997, 75, 1167-1172.
DOYLE L. et al., A multidrug resistance transporter from human MCF-7 breast cancer
cells, Proc. Nat/. Acad. Sei., États-Unis, 1998, 95, 15665-15670.
HAZLEHURST LA. et al., Chromosome mediated gene transfer of drug resistance to
mitoxantrone, AnticancerRes., 1998, 18, 1005-1010.
LAGE H. et al., Expression of the novel mitoxantrone resistance associated gene MXR7
in colorectal malignancies, Int. Clin. Pharmacol. Ther., 1998, 36, 58-60.
ROSS D.D. et al., Atypical multidrug resistance : breast cancer resistance protein mes-
senger RNA expression in mitoxantrone selected cell lines, J. Natl. CancerInst., 1999,
91, 429-433.
GUTIERREZ P.l., The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactiva-
tion of quinone-containing antitumor agents : a review, Free Radie. Biol. Med., 2000,
29, 263-275.
PARKER B.S. et al., Formaldehyde activation of mitoxantrone yields CpG and CpA spe-
cific DNA adducts, Nucleic Acids Res., 2000, 28, 982-990.
SCHEFFER G.L. et al., Breast cancer resistance protein is localized at the plasma mem-
brane in mitoxantrone- and topotecan-resistant cell lines, Cancer Res., 2000, 60,
2589-2593.
SKLADANOWSKI A., KONOPA J., Mitoxantrone and ametantrone induce interstrand
cross-links in DNA of tumeur cells, Br. J. Cancer, 2000, 82, 1300-1304.

UTILISATION THÉRAPEUTIQUE, INCOMPATIBILITÉS,
PERSPECTIVES
FOLLEZOU J.-Y., Interaction of mitoxantrone with heparin and ils application to the
quantification of heparin, Thromb. Res., 1994, 74, 419-425.
HAZLEHURST L.A. et al., Correlation of DNA reactivity and cytotoxicity of a new class
of anticancer agents : aza-anthracene diones, Cancer Lett., 1995, 91, 115-124.
KRAPCHO A.P. et al., Anthracene-9,10-diones and aza-bioisosteres as antitumor
agents, Curr. Med. Chem., 1995, 2, 803-824.
TRISSEL L.A., MARTINEZ J.F., Compatibility of aztreonam with selected drugs during
simuiated Y-site administration, Am. J. Health-Syst. Pharm., 1995, 52, 1086-1090.
GONSETTE R.E., Mitoxantrone immunotherapy in multiple sclerosis, Mu/t. Scier, 1996,
1, 329-332.
SISSI C. et al., Aza-bioisosteres of 9, 10-anthracenedione : a modulation of DNA sequence
specificity, Mol. Pharmacol., 1996, 50, 838-845.
DE ISABELLA P. et al., Physicochemical properties, cytotoxic activity and topoisomerase
Il inhibition of 2,3-diaza-anthracene-diones, Biochem. Pharmacol., 1997, 53, 161-169.
Losoxantrone hydrochloride, Drugs Fut., 1997, 22, 911.
Piroxantrone, Drugs Fut., 1997, 22,315 et 1998, 23, 339.
SMITH P.J. et al., DNA topoisomerase 11-dependent cytotoxicity of alkylaminoanthraqui-
nones and their N-oxides, Cancer Chemother. Pharmacol., 1997, 39, 455-461.
WANG H. et al., Experimental antitumor activity of the Ce(lV) - mitoxantrone complex
and its interaction with deoxyribonucleic acid, J. Inorg. Biochem., 1997, 68, 117-121.